Please type a plus sign (+)	inside this box	Н	H
-----------------------------	-----------------	---	---

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 10

Complete if Known						
Application Number 10/549,445						
Filing Date July 31, 2006						
First Named Inventor	Shawn DEFREES					
Group Art Unit	1623					
Examiner Name	Patrick T. Lewis					
Attorney Docket Number	705759					
Client Reference No.	NEO00262US/371					

	U.S. PATENT DOCUMENTS					
		U.S. Patent Document				
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
,	AA	4,055,635		Green et al.	10-25-1977	
	AB	4,088,538		Schneider	05-09-1978	
	AC	4,179,337		Davis et al.	12-18-1979	
	AD	4,385,260		Watts	05-24-1983	
	AE	4,412,989		Iwashita et al.	11-01-1983	,
	AF	4,414,147		Klibanov et al.	11-08-1983	•
	AG	4,496,689		Mitra	01-29-1985	
	AH	4,565,653		Ives et al.	01-21-1986	
	Al	4,806,595		Noishiki et al.	02-21-1989	
	AJ	4,879,236		Smith et al.	11-07-1989	
	AK	4,925,796		Bergh et al.	05-15-1990	
	AL	5,147,788		Page et al.	09-15-1992	
	AM	5,153,265		Shadle et al.	10-06-1992	
	AN	5,154,924		Friden	10-13-1992	
	AO	5,169,933		Anderson et al.	12-08-1992	
	AP	5,182,107		Friden	01-26-1993	
	AQ	5,194,376		Kang	03-16-1993	
	AR	5,346,696		Kim et al.	09-13-1994	
	AS	5,352,670		Venot et al.	10-04-1994	
	AT	5,369,017		Wong et al.	11-29-1994	
	AU	5,374,541		Wong et al.	12-20-1994	
	AV	5,405,753		Brossmer et al.	04-11-1995	
	AW	5,432,059		Bean et al.	07-11-1995	
	AX	5,492,841		Craig	02-20-1996	
	AY	5,527,527		Friden	06-18-1996	
	AZ	5,545,553		Gotschlich	08-13-1996	
	BA	5,614,184		Sytkowski et al.	03-25-1997	
	BB	5,621,039		Hallahan et al.	04-15-1997	
	ВС	5,635,603		Hansen et al.	06-03-1997	
	BD	5,646,113		Attie et al.	07-08-1997	
	BE	5,672,683		Friden et al.	09-30-1997	
	BF	5,716,812		Withers et al.	02-10-1998	
	BG	5,728,554		Bayer et al.	03-17-1998	
	ВН	5,833,988		Friden	11-10-1998	
	BI	5,834,251		Maras et al.	11-10-1998	
	BJ	5,849,535		Cunningham et al.	12-15-1998	
	ВК	5,876,980		DeFrees et al.	03-02-1999	
	BL	5,922,577		DeFrees et al.	07-13-1999	
***	ВМ	5,932,462		Harris et al.	08-03-1999	
	BN	5,945,314		Prieto, et al.	08-31-1999	

Examiner Signature	Date Considered

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box $\longrightarrow$	
---	--

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 10

Complete if Known					
	Complete ii Known				
Application Number 10/549,445					
Filing Date July 31, 2006					
First Named Inventor	Shawn DEFREES				
Group Art Unit	1623				
Examiner Name	Patrick T. Lewis				
Attorney Docket Number	705759				
Client Reference No.	NEO00262US/371				

				U.S. PATENT DOCUMENTS		
U.S. Patent Document						
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	ВО	5,969,040		Hallahan et al.	10-19-1999	
	BP	5,977,307		Friden et al.	11-02-1999	
	BQ	6,015,555		Friden	01-18-2000	
	BR	6,030,815		DeFrees et al.	02-29-2000	
	BS	6,037,452		Minamino et al.	03-14-2000	
	вт	6,057,292		Cunningham et al.	05-02-2000	
	BU	6,087,325		Meers et al.	07-11-2000	-
	BV	6,096,512		Elhammer et al.	08-01-2000	
	BW	6,166,183		Ishikawa et al.	12-26-2000	
	BX	6,183,738	B1	Clark	02-06-2001	
	BY	6,261,805	B1	Wood	07-17-2001	
	BZ	6,362,254	B2	Harris et al.	03-26-2002	
	CA	6,440,703	B1	DeFrees	08-27-2002	
	CB	6,531,121	B2	Brines et al.	03-11-2003	
	CC	6,555,346	B1	Kretzdorn et al.	04-29-2003	
	CD	6,692,931	B1	Reutter et al.	02-17-2004	
	CE	7,125,843	B2	DeFrees et al.	10-24-2006	
	CF	7,138,371	B2	DeFrees et al.	11-21-2006	
	CG	7,202,208	B2	Papadimitriou	04-10-2007	
	СН	7,214,660	B2	DeFrees et al.	05-08-2007	
	CI	7,338,933	B2	DeFrees et al.	03-04-2008	
	CJ	7,405,198	B2	DeFrees et al	07-29-2008	
	CK	2002-0137134	A1	Gerngross et al.	09-26-2002	
	CL	2002-0150981	A1	Canfield	10-17-2002	
	СМ	2002-0168323	A1	Gonda	11-14-2002	
٧.	CN	2003-0027257	A1	latrou et al.	02-06-2003	
	CO	2004-0063911	A1	DeFrees et al.	04-01-2004	
	CP	2004-0136955	A1	Barker et al.	07-15-2004	10.
	CQ	2004-0137557	A1	DeFrees et al.	07-15-2004	
	CR	2005-0118672	A1	DeFrees et al.	06-02-2005	
	CS	2005-0143292	A1	DeFrees et al.	06-30-2005	
	CT	2006-0024286	A1	Glidden	02-02-2006	
	CU	2006-0111279	A1	DeFrees et al.	05-25-2006	
	CV	2007-0027068	A1	DeFrees et al.	02-01-2007	
	CW	2007-0105755	A1	DeFrees et al.	05-10-2007	
	CX	2008-0015142	A1	DeFrees et al.	01-17-2008	
•						
				<u> </u>		

Examiner Signature	Date Considered	

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box ->	$\mp$
--	-------

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 10

	Complete if Known					
Application Number	10/549,445					
Filing Date	July 31, 2006					
First Named Inventor	Shawn DEFREES					
Group Art Unit	1623					
Examiner Name	Patrick T. Lewis					
Attorney Docket Number	705759					
Client Reference No.	NEO00262US/371					

4				FORE	IGN PATENT DOCUMENTS		
	Foreign Patent Document						
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Translation *
	CY	EP	0474313	A2	Centro de Ingenieria Genetica y Biotecnologia	03-11-1992	
	CZ	EP	0585109	A2	Suntory Ltd.	03-02-1994	
	DA	EP	0605963	A2	Ortho Pharmaceutical Corp.	07-13-1994	
	DB	EP	1428878	A1	Bioceuticals Arzneimittel AG	06-16-2004	
	DC	WO	1987/000056	A1	Cetus Corp.	01-15-1987	
	DD	WO	1987/005330	A1	Bergh et al.	09-11-1987	
	DE	wo	1989/010134	A1	The Regents of the University of California	11-02-1989	
	DF	WO	1990/007572	A1	Genentech, Inc.	07-12-1990	
	DG	WO	1990/008164	A1	The Upjohn Co.	07-26-1990	
	DH	WO	1990/008823	A1	The Upjohn Co.	08-09-1990	
	DI	wo	1992/018135	A1	The Regents of the University of California	10-29-1992	
	DJ	WO	1994/005332	A2	Berlex Laboratories, Inc.	03-17-1994	
	DK	WO	1994/015625	A1	Enzon, Inc.	07-21-1994	-
	DL	WO	1995/002421	A1	Alkermes, Inc.	01-26-1995	
	DM	WO	1996/021469	A1	Shearwater Polymers, Inc.	07-18-1996	
	DN	WO	1996/032491	A1	Cytel Corp.	10-17-1996	
	DO	wo	1996/040731	A1	Mount Sinai School of Medicine of the City University of New York	12-19-1996	
	DP	wo	1997/005330	A1	Cytec Technology Corp.	02-13-1997	
	DQ	wo	1998/005363	A2	Ortho-McNeil Pharmaceutical, Inc.	02-12-1998	
	DR	WO	1998/031826	A1	Cytel Corp.	07-23-1998	
	DS	wo	1998/051784	A1	Phoenix Pharmacologics, Inc.	11-19-1998	
	DT	wo	1998/058964	A1	Genentech, Inc.	12-30-1998	
	DU	wo	1999/000150	A2	Regents of the University of California	01-07-1999	
	DV	WO	1999/045964	A1	Shearwater Polymers, Inc.	09-16-1999	
	DW	wo	2000/023114	A2	Biogen, Inc.	04-27-2000	
	DX	WO	2000/026354	A1	Novozymes A/S	05-11-2000	
	DY	WO	2000/065087	A1	AstraZeneca AB	11-02-2000	
	DZ	WO	2001/002017	A2	F. Hoffman-LaRoche AG	01/11/2001	
	EA	WO	2001/049830	A2	Maxygen APS	07-12-2001	
	EB	WO	2001/058935	A2	Maxygen APS	08-16-2001	
	EC	wo	2001/060411	A1	Kanagawa Academy of Science and Technology	08-23-2001	
	ED	wo	2002/002597	A2	Maxygen APS	01-10-2002	
	EE	wo	2002/002764	A2	Regents of the University of Minnesota	01-10-2002	

Examiner Signature	Date Considered	
Examiner dignature	Date Considered	

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box ->	+	_
--	---	---

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

10

Sheet 4 of

Complete if Known			
Application Number	10/549,445		
Filing Date	July 31, 2006		
First Named Inventor Shawn DEFREES			
Group Art Unit	1623		
Examiner Name	Patrick T. Lewis		
Attorney Docket Number	705759		
Client Reference No.	NEO00262US/371		

				FOREIGN	PATENT DOCUMENTS		
			Foreign Patent Document				
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Translation *
	EF	wo	2002/013843	A2	University of British Columbia; Gabathuler et al.	02-21-2002	
	EG	WO	2002/013873	A2	Synapse Technologies, Inc.	02-21-2002	
	EH	wo	2002/053580	A2	The Kenneth S. Warren Institute, Inc.	07-11-2002	
	EI	WO	2002/074806	A2	Maxygen APS	09-26-2002	
	EJ	wo	2002/092619	A2	The Government of the United States of America	11-21-2002	
	EK	wo	2003/017949	A2	Neose Technologies, Inc.	03-06-2003	
	EL	WO	2003/031464	A2	Neose Technologies, Inc.	04-17-2003	
	ЕМ	wo	2004/010327	A2	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	01-29-2004	
	EN	WO	2004/033651	A2	Neose Technologies, Inc.	04-22-2004	
	EO	wo	2004/096148	A2	The Kenneth S. Warren Institute, Inc.	11-11-2004	
	EP	wo	2004/099231	A2	Neose Technologies, Inc.	11-18-2004	
	EQ	wo	2004/103275	A2	Neose Technologies, Inc.	12-02-2004	
	ER	wo	2005/025606	A1	Warren Pharmaceuticals, Inc.	03-24-2005	
	ES	wo	2005/067601	A2	Neose Technologies, Inc.	07-28-2005	
	ET	wo	2005/070138	A2	Neose Technologies, Inc.	08-04-2005	
	EU	wo	2005/121331	A2	Neose Technologies, Inc.	12-22-2005	
	EV	wo	2006/014349	A2	The Kenneth S. Warren Institute, Inc.	02-09-2006	
	EW	wo	2006/014466	A2	The Kenneth S. Warren Institute, Inc.	02-09-2006	
	EX	wo	2006/031811	A2	Neose Technologies, Inc.	03-23-2006	
	EY	wo	2006/074279	A1	Neose Technologies, Inc.	07-13-2006	
	EZ	wo	2006/078645	A2	Neose Technologies, Inc.	07-27-2006	
	FA	wo	2008/011633	A2	Neose Technologies, Inc.	01-24-2008	

Examiner Signature	Date Considered	
	L	

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box $\rightarrow$	F
---	---

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

 Sheet
 5
 of
 10

Complete if Known			
Application Number	10/549,445		
Filing Date	July 31, 2006		
First Named Inventor	Shawn DEFREES		
Group Art Unit	1623		
Examiner Name	Patrick T. Lewis		
Attorney Docket Number	705759		
Client Reference No.	NEO00262US/371		

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	FB	ABEIJON et al., J. Biol. Chem., 261(24): 11374-11377 (1986).	
	FC	ABUCHOWSKI et al., J. Biol. Chem., 252(11): 3578-3581 (1977)	
	FD	ABUCHOWSKI et al., J. Biol. Chem., 252(11): 3582-3586 (1977)	
	FE	ABUCHOWSKI et al., Cancer Biochem. Biophys., 7(2): 175-186 (1984)	*****
	FF	AILOR et al., Glycobiology, 10(8): 837-847 (2000)	
	FG	ALAM et al., <i>J. Biotechnol.</i> , 65(2-3): 183-190 (1998)	
	FH	ALLEGRE et al., J. Memb. Sci., 269(1-2): 109-117 (2006)	
	FI	ALTMANN et al., Glycoconj. J., 16(2): 109-123 (1999)	
	FJ	APLIN et al., CRC Crit. Rev. Biochem., 10(4): 259-306 (1981)	****
	FK	BEAUCHAMP et al., Anal. Biochem., 131(1): 25-33 (1983)	
	FL	BEDARD et al., Cytotechnology, 15(1-3):129-138 (1994)	-
	FM	BENNETT et al., <i>J. Biol. Chem.</i> , 273(46): 30472-30481 (1998)	
	FN	BENNETT et al., <i>FEBS Lett.</i> , 460(2): 226-230 (1999)	
	FO	BERGER et al., <i>Blood,</i> 71(6): 1641-1647 (1988)	
	FP	BERG-FUSSMAN et al., <i>J. Biol. Chem.</i> , 268(20): 14861-14866 (1993)	
	FQ	BHADRA et al., <i>Pharmazie</i> , 57(1): 5-29 (2002)	
	FR	BHATIA et al., Anal. Biochem., 178(2): 408-413 (1989)	
	FS	BICKEL et al., <i>Adv. Drug Deliv. Rev.</i> , 46(1-3): 247-279 (2001)	7,1,1
	FT	BIJSTERBOSCH et al., <i>Eur. J. Biochem.</i> , 237(2): 344-349 (1996)	7.1
	FU	BJOERN et al., <i>J. Biol. Chem.</i> , 266(17): 11051-11057 (1991)	
	FV	BOCCU et al., Z. Naturforsch., 38c: 94-99 (1983)	
	FW	BOIME et al., Recent Prog. Horm. Res., 54: 271-289 (1999)	
	FX	BIOSSEL et al., <i>J. Biol. Chem.</i> , 268(21): 15983-15993 (1993)	
	FY	BORK et al., <i>Trends Genet.</i> , 12(10): 425-427 (1996)	
	FZ	BORK, <i>Genome Res.</i> , 10(4): 398-400 (200)	
	GA	BOUIZAR et al., <i>Eur. J. Biochem.</i> , 155(1): 141-147 (1986)	
	GB	BOYD et al., <i>Mol. Immunol.</i> , 32(17-18): 1311-1318 (1995)	
	GC	BRENNER, <i>Trends Genet.</i> , 15(4): 132-133 (1999)	
	GD	BROWNING et al., <i>J. Immunol.</i> , 143(6): 1859-1867 (1989)	
	GE	BUCKMANN et al., <i>Makromol. Chem.</i> , 182(5): 1379-1384 (1981)	
	GF	BURNS et al., <i>Blood</i> , 99(12): 4400-4405 (2002)	
	GG	BUTNEV et al., <i>Biol. Reprod.</i> , 58(2): 458-469 (1998)	
	GH	BYUN et al., ASAIO J., 38(3): M649-M653 (1992)	
	GI	CASARES et al., <i>Nat. Biotechnol.</i> , 19(2): 142-147 (2001)	
	GJ	CHAFFEE et al., <i>J. Clin. Invest.</i> , 89(5): 1643-1651 (1992)	
	GK	CHARTER et al., <i>Glycobiology</i> , 10(10): 1049-1056 (2000)	-
	GL	CHERN et al., Eur. J. Biochem., 202(2): 225-229 (1991)	
	GM	CHIBA et al., <i>Biochem. J.</i> , 308(2): 405-409 (1995)	
	GN	CHRISEY et al., <i>Nucleic Acids Res.</i> , 24(15): 3031-3039 (1996)	· · · · · · · · · · · · · · · · · · ·
	GO	CLARK et al., <i>J. Biol. Chem.</i> , 271(36): 21969-21977 (1996)	
	GP	COINTE et al., <i>Glycobiology</i> , 10(5): 511-519 (2000)	

Examiner Signature	Date Considered	

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

干
П

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 10

Complete if Known			
Application Number	10/549,445		
Filing Date	July 31, 2006		
First Named Inventor	Shawn DEFREES		
Group Art Unit	1623		
Examiner Name	Patrick T. Lewis		
Attorney Docket Number	705759		
Client Reference No.	NEO00262US/371		

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	GQ	CONRADT et al., J. Biol. Chem., 262(30): 14600-14605 (1987)	
	GR	COPE et al., Mol. Microbiol., 5(5): 1113-1124 (1991)	
	GS	COPELAND, "Enzymes: A Practical Introduction to Structure, Mechanism and Data Analysis" 2nd ed., Wiley-VCH, New York, p. 146-150 (2000)	
	GT	CROUT et al., Curr. Opin. Chem. Biol., 2(1): 98-111 (1998)	
	GU	DEFREES et al., Glycobiology, 16(9): 833-843 (2006)	
	GV	DELGADO et al., Biotechnol. Appl. Biochem., 12(2): 119-128 (1990)	
	GW	DELGADO et al., Crit. Rev. Ther. Drug Carrier Syst., 9(3-4): 249-304 (1992)	
	GX	DOERKS et al., <i>Trends Genet.</i> , 14(6): 248-250 (1998)	
	GY	DOUGLAS et al., J. Am. Chem. Soc., 113(13): 5095-5097 (1991)	
	GZ	DUNN, 1991, "Polymeric Drugs and Drug Delivery Systems" Dunn et al. (eds.), Chapter 2 "Polymeric Matrices", pp. 11–23, ACS Symposium Series Vol. 469, American Chemical Society, Washington D.C.	
	HA	DURIEUX et al., Tetrahedron Lett., 42(12): 2297-2299 (2001)	
	HB	DWEK et al., J. Anat., 187(Pt. 2): 279-292 (1995)	
	HC	EAVARONE et al., <i>J. Biomed. Mater. Res.</i> , 51(1): 10-14 (2000)	
	HD	FAN et al., J. Biol. Chem., 272(43): 27058-27064 (1997)	
	HE	FIBI et al., <i>Blood</i> , 85(5): 1229-1236 (1995)	
	HF	FISCHER et al., Thromb. Res., 89(3): 147-150 (1998)	
	HG	FLYNN et al., Curr. Opin. Oncol., 12(6): 574-581 (2000)	
	НН	FRITZ et al., Proc. Natl. Acad. Sci. USA, 101(43): 15307-15312 (2004)	
	HI	FRITZ et al., J. Biol. Chem., 281(13): 8613-8619 (2006)	
	HJ	GARNETT et al., Adv. Drug Deliv. Rev., 53(2): 171-216 (2002)	
	HK	GATOT et al., J. Biol. Chem., 273(21): 12870-12880 (1998)	
	HL	GILBERT et al., Cytotechnology, 22(1-3): 211-216 (1996)	
	НМ	GILLIS et al., Behring Inst. Mitt., 83: 1-7 (1988)	
	HN	GINNS, PEG Glucocerebrosidase, Internet page from www.gaucher.org.uk/peg2.prg, printed Jun. 21, 2002.	
	НО	GOTSCHLICH, J. Exp. Med., 180(6): 2181-2190 (1994)	
	HP	GRABENHORST et al., Eur. J. Biochem., 215(1): 189-197 (1993)	
	HQ	GRODBERG et al., Eur. J. Biochem., 218(2): 597-601 (1993)	
	HR	GROSS et al., <i>Biochemistry</i> , 28: 7386-7392 (1989)	
	HS	GROSS, Eur. J. Biochem., 203(1-2): 269-275 (1992)	
	HT	HAGEN et al., J. Biol. Chem., 274(10): 6797-6803 (1999)	
	HU	HAGEN et al., J. Biol. Chem., 276(20): 17395-17404 (2001)	
	HV	HALL, Methods Mol. Biol., 166: 139-154 (2001)	
	HW	HANEDA et al., Carbohydr. Res., 292: 61-70 (1996)	
	НХ	HANG et al., J. Am. Chem. Soc., 123(6): 1242-1243 (2001)	
	HY	HARRIS et al., <i>Nat. Rev. Drug Discov.</i> , 2(3): 214-221 (2003)	
	HZ	HARRIS et al., Abstracts of Papers of the American Chemical Society, V 201, APR, P 64-POLY, page 154-155 (1991)	

Examiner Signature	Date Considered	
Examinor orginaturo	Date Condidence	

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box $\longrightarrow$ $\lceil$ -	+
--	---

Sheet

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

10

(Ose as many shocks as necessary)

7

	Complete if Known
Application Number	10/549,445
Filing Date	July 31, 2006
First Named Inventor	Shawn DEFREES
Group Art Unit	1623
Examiner Name	Patrick T. Lewis
Attorney Docket Number	705759
Client Reference No.	NEO00262US/371

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	IA	HARRIS, J. Macromol. Science, Rev. Macromol. Chem. Phys., C25(3): 325-373 (1985)	
	IB	HASSAN et al., J. Biol. Chem., 275(49): 38197-38205 (2000)	
	IC	HAYES et al., J. Biol. Chem., 268(22): 16170-16178 (1993)	
	ID	HELLSTROM et al., Methods Mol. Biol., 166: 3-16 (2001)	
	ΙE	HERMANSON et al., Immobilized Affinity Ligand Techniques, Academic Press (1992)	
	IF	HERMANSON, Bioconjugate Techniques, Academic Press, San Diego (1996)	
	IG	HERMENTIN, et al., <i>Glycobiology</i> , 6(2): 217-230 (1996)	
	ΙH	HILLS et al., Am. Biotechnol. Lab., 20(11): 30 (2002)	
	11	HINK et al., Biotechnol. Prog., 7(1): 9-14 (1991)	
	IJ	HOLLISTER et al., Glycobiology, 11(1): 1-9 (2001)	
	IK	HOUNSELL et al., Glycoconj J., 13(1): 19-26 (1996)	
	IL	ICHIKAWA et al., J. Am. Chem. Soc., 114(24): 9283–9298 (1992)	
	IM	IKONOMOU et al., In Vitro Cell. Dev. Biol. Anim., 37(9): 549-559 (2001)	
	IN	INLOW et al., <i>J. Tissue Cult. Methods</i> , 12(1): 13-16 (1989)	
	10	INOUE et al., Biotechnol. Annu. Rev., 1: 297-313 (1995)	
	IP	ITO et al., Pure Appl. Chem., 65(4): 753-762 (1993)	
	IQ	JACKSON et al., <i>Anal. Biochem.</i> , 165(1): 114-127 (1987)	
	IR	JARVIS et al., <i>Curr. Opin. Biotechnol.</i> , 9(5): 528-533 (1998)	
	IS	JOPPICH et al., <i>Makromol. Chem.</i> , 180: 1381-1384 (1979)	
	IT	JOSHI et al., <i>J. Biol. Chem.</i> , 265(24): 14518-14525 (1990)	
	ΙU	JUNG et al., <i>Biochim. Biophys. Acta</i> , 761(2): 152-162 (1983)	-
	IV	KAJIHARA et al., Carbohydrate Research, 315: 137-141 (1999)	
	IW	KALSNER et al., <i>Glycoconj. J.</i> , 12(3): 360-370 (1995)	
	IX	KASINA et al., <i>Bioconjug. Chem.</i> , 9(1): 108-117 (1998)	
	IY	KATRE et al., <i>Proc. Natl. Acad. Sci. USA</i> , 84(6): 1487-1491 (1987)	
	IZ	KEPPLER et al., Glycobiology, 11(2): 11R-18R (2001)	
	JA	KITAMURA et al., <i>Biochem. Biophys. Res. Commun.</i> , 171(3): 1387-1394 (1990)	+
	JB	KITAMURA et al., Cancer Res., 51(16): 4310-4315 (1991)	
	JC	KODAMA et al., Tetrahedron Lett., 34(40): 6419-6422 (1993)	
	JD	KOELLER et al., Nat. Biotechnol., 18(8): 835-841 (2000)	
	JE	KOELLER et al., <i>Nature</i> , 409(6817): 232-240 (2001)	
	JF	KOIDE et al., <i>Nature</i> , 409(0817). 232-240 (2001)  KOIDE et al., <i>Biochem. Biophys. Res. Commun.</i> , 111(2): 659-667 (1983)	
	JG	KREITMAN, Curr Pharm Biotechnol., 2(4): 313-325 (2001)	-
	JH	KUHN et al., <i>J. Biol. Chem.</i> , 270(49): 29493-29497 (1995)	
	JI	LAI et al, J. Biol. Chem., 261(7): 3116-3121 (1986)	
	JJ	LAU et al., <i>J. Biotechnol.</i> , 75(2-3): 105-115 (1999)	
	JK	LEE et al., <i>Biochemistry</i> , 28(4): 1856-1861 (1989)	
	JL	LEE-HUANG et al., <i>Proc. Natl. Acad. Sci. USA</i> , 81(9): 2708-2712 (1984)	
	JM	LEUNG, J Immunol. 154(11): 5919-5926 (1995)	
	JN	LI et al., <i>Trends Pharmacol. Sci.</i> , 23(5): 206-209 (2002)	
	JO	LI et al., Med. Res. Rev., 22(3): 225-250 (2002)	

Examiner Signature	Date Considered	

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box $\longrightarrow$
---

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 10

Complete if Known		
Application Number	10/549,445	
Filing Date	July 31, 2006	
First Named Inventor	Shawn DEFREES	
Group Art Unit	1623	
Examiner Name	Patrick T. Lewis	
Attorney Docket Number	705759	
Client Reference No.	NEO00262US/371	

		OTHER - NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	JP	LICARI et al., <i>Biotechnol. Bioeng.</i> , 39(4): 432-441 (1992)	
	JQ	LICARI et al., <i>Biotechnol. Bioeng.</i> , 39(9): 932-944 (1992)	
	JR	LIU et al., Chem. Eur. J., 2(11): 1359-1362 (1996)	
	JS	LONG et al., Exp. Hematol., 34(6): 697-704 (2006)	
	JT	LORD et al., Clin. Cancer Res., 7(7): 2085-2090 (2001)	
	JU	LOUGHEED et al., J. Biol. Chem., 274(53): 37717-37722 (1999)	
	JV	LUCKOW et al., Curr. Opin. Biotechnol., 4(5): 564-572 (1993)	
	JW	LUND et al., FASEB J., 9(1): 115-119 (1995)	
	JX	LUND et al., J. Immunol., 157(11): 4963-4969 (1996)	
	JY	MAHAL et al., Science, 276(5315): 1125-1128 (1997)	
	JZ	MARANGA et al., Biotechnol. Bioeng., 84(2): 245-253 (2003)	
	KA	MARAS et al., J Biotechnol., 77(2-3): 255-263 (2000)	
	KB	MILLER, Curr. Opin. Genet. Dev., 3(1): 97-101 (1993)	
	KC	MIN et al., Endocr. J., 43(5): 585-593 (1996)	
	KD	MISTRY et al., Lancet, 348(9041): 1555-1559 (1996)	
	KE	MORIMOTO et al., Glycoconj. J., 13(6): 1013-1020 (1996)	
	KF	NCBI - Accession No. NCAA26095 (2 pgs.)	
	KG	NCBI - Accession No. NP_058697 (3 pgs.)	
	KH	NCBI - Accession No. NP_999299 (2 pgs.)	
	KI	NCBI Database hits for erythropoietin protein sequences (3 pgs.)	
		NGO et al., "The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14:	
	KJ	Computational Complexity Protein Structure Prediction, and the Levinthal Paradox," pp.	
		433-440 and 492-495 (1994)	
	KK	NILSSON et al., <i>Methods Enzymol.</i> , 104: 56-69 (1984)	
	KL	O'CONNELL et al., J. Biol. Chem., 267(35): 25010-25018 (1992)	
	KM	OETKE et al., J. Biol. Chem., 277(8): 6688-6695 (2002)	
	KN	OLSON et al., J. Biol. Chem., 274(42): 29889-29896 (1999)	
	KO	PALACPAC et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96(8): 4692-4697 (1999)	
	KP_	PARK et al., J. Biol. Chem., 261(1): 205-210 (1986)	
	KQ	PAULSON et al., <i>J. Biol. Chem.</i> , 252(23): 8624-8628 (1977)	
	KR	PLUMMER et al., J. Biol. Chem., 270(22): 13192-13196 (1995)	
	KS	PNGase-F Amidase Sequence from F. Meningosepticum (Registry Numbers 128688-70-0)	
	KT	PNGase-F Amidase Sequence from F. Meningosepticum (Registry Numbers 128688-71-1)	
	KU	PYATAK et al., Res. Commun. Chem. Pathol. Pharmacol., 29(1): 113-127 (1980)	
	ΚV	RABOUILLE et al., <i>J Cell Sci.</i> , 112(Pt. 19): 3319-3330 (1999)	
	KW	REFF et al., Cancer Control, 9(2): 152-166 (2002)	
	KX	ROSENTHAL et al., <i>Methods Enzymol.</i> , 235: 253-285 (1994)	
	KY	SADLER et al., <i>Methods Enzymol.</i> , 83: 458-514 (1982)	
	KZ	SANDBERG et al., Semin. Hematol., 38(2 Suppl. 4): 4-12 (2001)	

Examiner Signature	Date Considered

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box ->	+
--	---

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 10

Complete if Known		
Application Number	10/549,445	
Filing Date	July 31, 2006	
First Named Inventor	Shawn DEFREES	
Group Art Unit	1623	
Examiner Name	Patrick T. Lewis	
Attorney Docket Number	705759	
Client Reference No.	NEO00262US/371	

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	LA	SANEYOSHI et al., <i>Biol. Reprod.</i> , 65(6): 1686-1690 (2001)	
	LB	SAXON et al., Science, 287(5460): 2007-2010 (2000)	
	LC	SCHLAEGER, Cytotechnology, 20(1-3): 57-70 (1996)	
	LD	SCHWIENTEK et al., Gene, 145(2): 299-303 (1994)	
40.4440	LE	SCHWIENTEK et al., J. Biol. Chem., 277(25): 22623-22638 (2002)	
	LF	SCOUTEN, Methods Enzymol., 135: 30-65 (1997)	
	LG	SHAH et al., J. Pharm. Sci., 85(12): 1306-1311 (1996)	
	LH	SHAPIRO et al., <i>Blood</i> , 105(2): 518-525 (2005)	
	LI	SINGH et al., Chem. Commun., 1996(8): 993-994 (1996)	
	LJ	SINHA et al., Infect. Immun., 29(3): 914-925 (1980)	
	LK	SKOLNICK et al., Trends Biotechnol., 18(1): 34-39 (2000)	
	LL	SMITH et al., Nat. Biotechnol., 15(12): 1222-1223 (1997)	
	LM	SONG et al., J. Pharmacol. Exp. Ther., 301(2): 605-610 (2002	
	LN	SRINIVASACHAR et al., <i>Biochemistry</i> , 28(6): 2501-2509 (1989)	
	LO	STEPHENS et al., Eur. J. Biochem., 133(1): 155-162 (1983)	
	LP	STEPHENS et al., Eur. J. Biochem., 133(3): 481-489 (1983)	
	LQ	STEPHENS et al., Eur. J. Biochem., 135(3): 519-527 (1983)	
	LR	TAKANE et al., J Pharmacol Exp Ther., 294(2): 746-752 (2000)	
	LS	TAKEDA et al., <i>Trends Biochem. Sci.</i> , 20(9): 367-371 (1995)	
	LT	TAKEUCHI et al., <i>J. Biol. Chem.</i> , 265(21): 12127-12130 (1990)	
	LU	TANIGUCHI et al., <i>Proteomics</i> , 1(2): 239-247 (2001)	
	LV	TANNER et al., Biochim. Biophys. Acta, 906(1): 81-99. (1987)	
	LW	TAYLOR et al., Protein Immobilization Fundamentals and Applications, Manual (1991)	
	LX	TEN HAGEN et al., J. Biol. Chem., 274(39): 27867-27874 (1999)	
	LY	TENNO et al., J. Biol. Chem., 277(49): 47088-47096 (2002)	
	LZ	THOTAKURA et al., Methods Enzymol., 138: 350-9 (1987)	
	MA	TSUBOI et al., Arch. Biochem. Biophys., 374(1): 100-106 (2000)	
	MB	TUDDENHAM, Nature, 419(6902): 23-24 (2002)	
	MC	UDENFRIEND et al., Annu. Rev. Biochem., 64: 563-591 (1995)	
	MD	ULLOA-AGUIRRE et al., <i>Endocrine,</i> 11(3): 205-215 (1999)	
	ME	ULUDAG et al., Biotechnol. Prog., 18(3): 604-611 (2002)	
	MF	URDAL et al, J. Chromatogr., 296: 171-179 (1984)	
	MG	VAN BERKEL et al., <i>Biochem. J.,</i> 319(Pt. 1): 117-122 (1996)	
	МН	VAN REIS et al., <i>Biotechnol. Bioeng.</i> , 38(4): 413-422 (1991)	
	MI	VERONESE et al., Appl. Biochem. Biotechnol., 11(2): 141-152 (1985)	
	MJ	VOCADLO et al., "Glycosidase-Catalysed Oligosaccharide Synthesis" in Carbohydrate Chemistry and Biology, Vol. 2, Chapter 29, pp. 723-844 (2000)	
	MK	VYAS et al., Crit. Rev. Ther. Drug Carrier Syst., 18(1): 1-76 (2001)	
	ML	WANG et al., Tetrahedron Lett., 37(12): 1975-1978 (1996)	
	MM	WANG et al., <i>Protein Eng.</i> , 11(12): 1277-1283 (1998)	

Examiner Signature	Date Considered	

<sup>\*</sup> If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box ->	+
--	---

Substitute	for form	1449A/B/PTO	

Sheet

#### **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

10

10

Complete if Known			
Application Number	10/549,445		
Filing Date	July 31, 2006		
First Named Inventor	Shawn DEFREES		
Group Art Unit	1623		
Examiner Name	Patrick T. Lewis		
Attorney Docket Number	705759		
Client Reference No.	NEO00262US/371		

		OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	MN	WELLHONER et al., J. Biol. Chem., 266(7): 4309-4314 (1991)	
	MO	WELLS, Biochemistry, 29(37): 8509-8517 (1990)	
	MP	WITTE et al., J. Am. Chem. Soc., 119(9): 2114–2118 (1997)	
	MQ	WOGHIREN et al., <i>Bioconjug. Chem.</i> , 4(5): 314-318 (1993)	
	MR	WONG et al., J. Org. Chem., 47(27): 5416–5418 (1982)	
	MS	WONG et al., Enzyme Microb Technol., 14(11): 866-874 (1992)	
	MT	WONG et al., Biotechnol. Bioeng., 49(6): 659-666 (1996)	
	MU	WOODS et al., Eur. J. Cell Biol., 50(1): 132-143 (1989)	
	MV	WRIGHT et al., <i>J. Immunol.</i> , 160(7): 3393-3402 (1998)	
	MW	WU et al., J. Drug Target., 10(3): 239-245 (2002)	
	MX	XING et al., Biochem. J., 336(Pt. 3): 667-673 (1998)	
	MY	YAMAMOTO et al., Carbohydr. Res., 305(3-4): 415-422 (1997)	
	MZ	YAREMA et al., J. Biol. Chem., 273(47): 31168-31179 (1998)	
	NA	YOSHIDA et al., Glycobiology, 9(1): 53-58 (1999)	
	NB	YOSHITAKE et al., <i>Biochemistry</i> , 24(14): 3736-3750 (1985)	
	NC	ZALIPSKY et al., "Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides" in <i>Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications</i> , Harris (ed.), Chapter 21, pp. 347-370 (Plenum Press, New York, 1992)	-3-
	ND	ZALIPSKY, Bioconjug. Chem., 6(2): 150-165 (1995)	
	NE	ZHENG et al., Biotechnol. Bioeng., 65(5): 600-604 (1999)	
	NF	ZHOU et al., 1994, Mol. Microbiol., 14(4): 609-618 (1994)	

Examiner Signature	Date Considered	

If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.